MaaT Pharma announced the appointment of Nathalie Corvaia, Ph.D., as Chief Scientific Officer. Dr. Corvaia brings more than 20 years of experience leading drug discovery and development programs in oncology and guiding the advancement of product candidates into the clinic. She will oversee MaaT Pharma's non-clinical research and development strategies as well as the Company's proprietary, AI-based MET drug design and development platform, gutPrint.

MaaT Pharma has established clinical proof of concept for its high-richness, high-diversity, native, donor-derived MET-N approach, with more than 140 patients treated in Europe to date in haemato-oncology with its drug candidates MaaT013 (for the treatment of aGvHD[1]) and MaaT033 (for the treatment of patients receiving allo-HSCT[2]), with promising safety and efficacy results. MaaT Pharma is now consolidating its second-generation drug development platform, MET-C. Leveraging its gutPrint AI[3] suite and groundbreaking ecosystem co-culture technology, MET-C allows the design and manufacturing of indication-specific, donor-independent 'MaaT03X' candidates. The platform opens new opportunities for the Company to address larger, and growing markets such as solid tumors, as well as to broaden its indication focus and potentially target other immune- and inflammatory-related diseases.